Amgen 'encouraged' by weight-loss drug interim data, shares jump

[cafead]

via Amgen (AMGN.O on Thursday said it was very encouraged after completing an interim analysis of its mid-stage study of experimental weight-loss drug MariTide and will no longer develop its oral obesity candidate AMG786.

article source